医药股随A股同业造好金嗓子(06896.HK)续涨9%创52周高里昂建议长线投资者趁低吸纳医药股
里昂上周四建议长线投资者藉回调吸纳医药股,本港医药板块今天普遍随A股同业造好,尤其是金嗓子(06896.HK)三连涨最多累涨23%,高见1.72元,创52周新高,现造1.69元,续涨9%,成交增至206万股。该公司去年多赚66.5%至1.02亿元人民币,末期股息12港仙(已於5月23日除净)。
药明康德(02359.HK)升破50天线(64.72元),最高见72元,现造67元,续升5%;其A股升3.4%高见86.68元人民币。旗下新药临床试验获批的复星医药(02196.HK)曾一举重越10天及20天线(21.93元及22.68元),最高见23.05元,现造22.45元,回升3.5%;其A股升4.5%高见24.99元人民币。
蓝筹中生(01177.HK)旗下抗真菌药获国家药监局药品注册批件,股价三连弹兼重越100天及10天线,最高见7.37元,现造7.28元,续升2.5%;蓝筹石药(01093.HK)回升1.7%曾高见11.8元;三生制药(01530.HK)反覆回升1.4%高见12.84元。联邦制药(03933.HK)升2%高见4.03元。威高股份(01066.HK)回升3.2%报7.32元,股价重越50天线(7.18元)。白云山(00874.HK)反覆升3%报33.85元,股价重越10天及、20天及100天线(33.84元)。
内地医药板块今天跑赢大市,其中生物医药板块造好,且11只个股涨停。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.